Form 8-K · Current report
Philip Morris International 8-K, filed Jul 22, 2026
- Filed
- CIK
- 0001413329
- Accession no.
- 0001628280-26-049107
Summary
Philip Morris International reported 2026 second-quarter results on July 22, with net revenues up 10.4% to $11.2 billion and adjusted diluted EPS up 15.2% to $2.20, while reported diluted EPS fell 7.7% to $1.80 on a non-cash impairment of its RBH equity investment, and the company updated its full-year adjusted diluted EPS forecast for currency only. Group CEO Jacek Olczak said the first half leaves PMI well positioned to deliver full-year targets.
Key points
- Second-quarter net revenues rose 10.4% (7.6% organically) to $11.2 billion, with smoke-free products at about 42% of the total and available in 109 markets.
- IQOS shipment volumes grew 7.6% in the quarter, though adjusted in-market sales in Japan and Poland were hit by an excise-driven price increase and a characterizing flavor ban.
- On June 30 the FDA granted modified-risk tobacco product authorization to 20 variants of the flagship ZYN range, the first for a nicotine pouch product.
- PMI plans to launch 1.5mg and 8mg dry ZYN variants in the third quarter and is preparing for a future U.S. launch of IQOS ILUMA.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 2.02Results of Operations and Financial Condition
- 9.01Financial Statements and Exhibits
From the filing
Item 2.02. Results of Operations and Financial Condition. On July 22, 2026, Philip Morris International Inc. (the “Company”) issued a press release announcing its financial results for the second quarter and the first half-year ended June 30, 2026, as well as the accompanying glossary of key terms, definitions, explanatory notes, select financial information and reconciliations of non-GAAP financial measures. The earnings release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference to this Item 2.02. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.